Saroja Pharma Industries India Limited is a specialized player in the pharmaceutical supply chain, focusing on the sourcing, trading, and manufacturing of **Active Pharmaceutical Ingredients (APIs)**, **Pharma Intermediates**, **Specialty Chemicals**, and **Solvents**. Established in **2019** and headquartered in **Mumbai**, the company serves both the human and veterinary medicinal markets. Saroja Pharma is currently executing a high-stakes strategic pivot, transitioning from a pure-play trading entity into a direct manufacturer to capture higher margins and secure its supply chain. --- ### **Strategic Pivot: From Trading to Integrated Manufacturing** The company is moving away from its legacy model of chemical procurement and distribution toward becoming a specialized manufacturer. This transition is designed to leverage its existing global customer database and deep market knowledge. * **Greenfield Manufacturing Facility:** The company is developing a new manufacturing hub to facilitate its entry into **API Pharma** production. * **Total Land Area:** **16,000 sq. meters** of Industrial NA land. * **Estimated Project Cost:** **₹23 Crore**. * **Strategic Location:** Situated in Maharashtra, **10-12 km** from the **Samrudhi Highway** and **2-3 km** from the **Shirdi-Ghoti Highway**, providing superior logistical connectivity. * **Timeline:** Diversification into direct **API manufacturing** is targeted within **one year**. * **CRAMS & Custom Synthesis:** The company is positioning itself to offer **Contract Research and Manufacturing Services (CRAMS)**, targeting global pharmaceutical players who require specialized intermediate synthesis. --- ### **Specialized Product Portfolio & Industrial Applications** Saroja Pharma operates within the **Chemicals and Pharmaceutical Intermediates** segment, focusing on complex chemical synthesis and high-value niche applications. | Category | Key Products | Primary Applications | | :--- | :--- | :--- | | **Pharma Intermediates** | **Para Nitro Phenol (PNP)** | Essential precursor for **Paracetamol (Acetaminophen)**; leverages India's cost advantages in analgesics. | | **Specialized Intermediates** | **Sulfonamide derivatives** | Used in treatments for **Hypertension**, **Cardiovascular diseases**, and **Metabolic disorders**. | | **Specialty Chemicals** | **Liquid Bromine, Ethyl Acetate, Thionyl Chloride** | Flame retardants, solvents, and precursors for antibiotics; **Thionyl Chloride** also serves as an electrolyte in the **Lithium-ion battery** industry. | | **Veterinary APIs** | **Antibiotics, Antiparasitics, Vaccines** | Tailored to animal-specific physiological needs; focus on high-value livestock and companion animals. | --- ### **Financial Performance & Capital Structure** The company has demonstrated resilience, showing a recovery in revenue and profitability in the most recent fiscal period following a contraction in **FY 2023-24**. #### **Three-Year Financial Summary** | Particulars (₹ in Crore) | FY 2024-25 (Interim) | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Income** | **53.73** | **40.67** | **50.35** | | **Profit After Tax (PAT)** | **1.03** | **0.88** | **1.06** | | **Basic EPS (₹)** | **2.49** | **2.49** | **3.61** | #### **Capital & Shareholding Details** * **Initial Public Offering (IPO):** Successfully completed on **September 13, 2023**, raising **₹9.11 Crore** by issuing **1,084,800 shares** at **₹84** per share (including a **₹74 premium**). * **Paid-up Share Capital:** **₹4.02 Crore** consisting of **40,20,486** equity shares. * **Promoter Holding:** **Biju Gopinathan Nair** holds a dominant **72.05%** stake as of March 2025. * **Dividend Policy:** The Board has **not recommended a dividend** for the recent fiscal years, opting to reinvest all profits into **Reserves** to fund the manufacturing expansion. --- ### **Geographical Footprint & Market Expansion** While the domestic Indian market remains the primary revenue driver, Saroja Pharma is aggressively expanding its international footprint, particularly in the **Asia-Pacific** and **European** regions. | Region | FY 2023-2024 (₹ in Lakhs) | FY 2022-2023 (₹ in Lakhs) | | :--- | :--- | :--- | | **India** | **3,343.09** | **4,500.34** | | **Asia Pacific** | **608.45** | **466.26** | | **Europe** | **86.69** | **4.59** | | **Total Revenue** | **4,038.23** | **4,971.22** | * **Growth Drivers:** Rising global demand for chronic disease treatments and the expansion of the **lithium-ion battery** sector. * **Emerging Markets:** Strategic plans to expand supply chain networks into **Latin America** and **Africa**. --- ### **Operational Excellence & Technological Integration** To maintain competitiveness and regulatory compliance, the company has integrated advanced technology across its operations: * **IT Infrastructure:** Utilizes a robust **ERP system** to manage logistics and cash flow, specifically designed to minimize **product shortages, pilferage, and out-of-stock situations**. * **Advanced Synthesis:** Implementation of **Continuous Flow Chemistry**, **solvent-free reactions**, and **new catalytic processes** to enhance yields and reduce environmental impact. * **Quality Control:** Utilization of **High-Performance Liquid Chromatography (HPLC)** to ensure products meet **FDA (U.S.)**, **EMA (Europe)**, and **ICH** standards. --- ### **Risk Profile & Industry Challenges** Investors should note the following risks inherent in the company’s transition and the broader pharmaceutical landscape: * **Regulatory & Environmental Compliance:** Stricter global regulations regarding **Volatile Organic Compounds (VOC)** and hazardous material handling (e.g., **Thionyl Chloride**) increase operational costs. * **Antimicrobial Resistance (AMR):** Tighter restrictions on antibiotic use in livestock may impact traditional veterinary API demand, necessitating a shift toward **Biologics** and **Vaccines**. * **Supply Chain & Input Costs:** High dependency on raw materials from **China** and **India** exposes the company to price volatility and geopolitical trade barriers. * **Governance & Execution:** Recent leadership changes, including the **September 2025 resignation** of a Whole-Time Director, and potential delays in the **Nashik factory** project execution remain key monitoring points. * **Sustainability Shift:** The industry-wide move toward **Green Chemistry** requires continuous capital expenditure to replace traditional solvents (like Toluene) with greener alternatives (like Ethyl Acetate).